STOCK TITAN

BioAffinity Technologies Inc - BIAFW STOCK NEWS

Welcome to our dedicated news page for BioAffinity Technologies (Ticker: BIAFW), a resource for investors and traders seeking the latest updates and insights on BioAffinity Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioAffinity Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioAffinity Technologies's position in the market.

Rhea-AI Summary
bioAffinity Technologies acquires Precision Pathology Services to support commercialization of CyPath® Lung test. The acquisition cost $3.5 million in cash and stock. The transaction aims to accelerate market uptake, support FDA pivotal trial, and develop additional tests. Precision Pathology offers a range of laboratory services. Dr. Roby Joyce joins bioAffinity's board of directors. Conference call at 4:30 p.m. ET today.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.63%
Tags
-
Rhea-AI Summary
bioAffinity Technologies to present corporate update and hold meetings with investors at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
conferences
-
Rhea-AI Summary
bioAffinity Technologies reports financial results for Q2 2023 and provides business update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
none
-
Rhea-AI Summary
bioAffinity Technologies, Inc. will present research findings at the University of Massachusetts RNA Therapeutics Symposium. The study shows that deprivation of vitamin B12 does not play a role in the selective cytotoxicity of cancer cells after silencing specific genes. The company aims to develop targeted therapeutics for multiple cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.87%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
none
Rhea-AI Summary
bioAffinity Technologies, Inc. has reported financial results for Q1 2023. Highlights include the appointment of a new CFO, progress in the branding and marketing strategy for CyPath® Lung, and positive clinical validation study results. The company plans to expand the commercial launch of CyPath® Lung and conduct a pivotal clinical trial. Revenue for Q1 2023 was $1,000, compared to no revenue in the prior-year period. Net loss for Q1 2023 was $1.5 million. Cash and cash equivalents as of March 31, 2023, were $9.8 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.13%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.78%
Tags
none
BioAffinity Technologies Inc

Nasdaq:BIAFW

BIAFW Rankings

BIAFW Stock Data

7.77M
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
San Antonio

About BIAFW

addressing a critical need to find cancer early and treat cancer specifically bioaffinity technologies, inc. develops tests and therapies to detect and treat cancer at the cellular level. our first product, cypath® flow cytometry for lung cancer (cypath® lung), has been licensed by precision pathology services for continued development and commercial sale as a laboratory developed test. cypath® lung has the potential to dramatically increase overall diagnostic accuracy leading to increased survival, fewer unnecessary invasive procedures and lower patient anxiety and medical costs.